Chronic exposure to low doses of dioxin promotes liver Fibrosis development in the C57BL/6J diet-induced obesity mouse model

Environmental Health Perspectives

Volumn 125, Issue 3, 2017, Pages 428-436

  Duval, Caroline ^a,b   Teixeira Clerc, Fatima ^c,d   Leblanc, Alix F ^a,b   Touch, Sothea ^e,f   Emond, Claude ^g   Guerre Millo, Michèle ^e,f   Lotersztajn, Sophie ^c,d   Barouki, Robert ^a,b,h   Aggerbeck, Martine ^a,b   Coumoul, Xavier ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e Sorbonne Universités   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AMINOTRANSFERASE; AROMATIC HYDROCARBON RECEPTOR; COLLAGEN; DIOXIN; GLUCOSE; MESSENGER RNA; TRIACYLGLYCEROL; POLLUTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET INDUCED OBESITY; FATTY LIVER; GENE EXPRESSION; HISTOLOGY; INFLAMMATION; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER FAILURE; LIVER FIBROSIS; LONG TERM EXPOSURE; LOW FAT DIET; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PERSISTENT ORGANIC POLLUTANT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; LIVER CIRRHOSIS; POLLUTANT; TOXICITY; TOXICITY TESTING;

ANIMALS; DIOXINS; DISEASE MODELS, ANIMAL; ENVIRONMENTAL POLLUTANTS; LIVER CIRRHOSIS; MICE; MICE, INBRED C57BL; TOXICITY TESTS, CHRONIC;

EID: 85014352511     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/EHP316     Document Type: Article

References (52)

1. Ambolet-Camoit A, Ottolenghi C, Leblanc A, Kim MJ, Letourneur F, Jacques S, et al. 2015. Two persistent organic pollutants which act through different xenosensors (alpha-endosulfan and 2,3,7,8 tetrachlorodi benzo-p-dioxin) interact in a mixture and downregulate multiple genes involved in human hepatocyte lipid and glucose metabolism. Biochimie 116:79–91, doi: 10.1016/j. biochi.2015.07.003.
2. Angrish MM, Jones AD, Harkema JR, Zacharewski TR. 2011. Aryl hydrocarbon receptor-mediated induction of stearoyl-CoA desaturase 1 alters hepatic fatty acid composition in TCDD-elicited steatosis. Toxicol Sci 124:299–310, doi: 10.1093/toxsci/kfr226.
3. Angrish MM, Mets BD, Jones AD, Zacharewski TR. 2012. Dietary fat is a lipid source in 2,3,7,8-tetrachloro dibenzo-ρ-dioxin-elicited hepatic steatosis in C57BL/6 mice. Toxicol Sci 128:377–386, doi: 10.1093/toxsci/kfs155.
4. Angulo P. 2002. Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231, doi: 10.1056/NEJMra011775.
5. Arciello M, Gori M, Maggio R, Barbaro B, Tarocchi M, Galli A, et al. 2013. Environmental pollution: a tangible risk for NAFLD pathogenesis. Int J Mol Sci 14:22052–22066, doi: 10.3390/ijms141122052.
6. Barouki R, Aggerbeck M, Aggerbeck L, Coumoul X. 2012. The aryl hydrocarbon receptor system. Drug Metabol Drug Interact 27:3–8, doi: 10.1515/dmdi-2011-0035.
7. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. 2011. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 54:773–794, doi: 10.1016/j. jhep.2010.11.006.
8. Benhamed F, Denechaud PD, Lemoine M, Robichon C, Moldes M, Bertrand-Michel J, et al. 2012. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest 122:2176–2194, doi: 10.1172/JCI41636.
9. Boverhof DR, Burgoon LD, Tashiro C, Chittim B, Harkema JR, Jump DB, et al. 2005. Temporal and dose-dependent hepatic gene expression patterns in mice provide new insights into TCDD-mediated hepatotoxicity. Toxicol Sci 85:1048–1063, doi: 10.1093/toxsci/kfi162.
10. Cave M, Appana S, Patel M, Falkner KC, McClain CJ, Brock G. 2010. Polychlorinated biphenyls, lead, and mercury are associated with liver disease in American adults: NHANES 2003–2004. Environ Health Perspect 118:1735–1742, doi: 10.1289/ehp.1002720.
11. CDC (Centers for Disease Control). 1988. Preliminary report: 2, 3, 7, 8-tetrachl orodi benzo-p-di oxi n exposure to humans—Seveso, Italy. MMWR Morb Mortal Wkly Rep 37(48):733–736.
12. Choi SS, Diehl AM. 2008. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Li pi dol 19: 295–300, doi: 10.1097/MOL.0b013e3282ff5e55.
13. Consonni D, Pesatori AC, Zocchetti C, Sindaco R, D’Oro LC, Rubagotti M, et al. 2008. Mortality in a population exposed to dioxin after the Seveso, Italy, accident in 1976: 25 years of follow-up. Am J Epidemiol 167:847–858, doi: 10.1093/aje/kwm371.
14. Cui G, Qin X, Wu L, Zhang Y, Sheng X, Yu Q, et al. 2011. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Invest 121:658–670, doi: 10.1172/JCI42974.
15. Denison MS, Nagy SR. 2003. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43:309–334, doi: 10.1146/annurev.pharmtox.43.100901.135828.
16. Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B. 2002. The role of PPARs in atherosclerosis. Trends Mol Med 8: 422–430, doi: 10. 1016/S1471-4914(02)02385-7.
17. Duval C, Thissen U, Keshtkar S, Accart B, Stienstra R, Boekschoten MV, et al. 2010. Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57Bl/6 mice. Diabetes 59:3181–3191, doi: 10.2337/db10-0224.
18. Emond C, Michalek JE, Birnbaum LS, DeVito MJ. 2005. Comparison of the use of a physiologically based pharmacokinetic model and a classical pharmacokinetic model for dioxin exposure assessments. Environ Health Perspect 113:1666–1668, doi: 10.1289/ehp.8016.
19. Eskenazi B, Mocarelli P, Warner M, Needham L, Patterson DG Jr, Samuels S, et al. 2004. Relationship of serum TCDD concentrations and age at exposure of female residents of Seveso, Italy. Environ Health Perspect 112:22–27, doi: 10.1289/ehp.6573.
20. He J, Hu B, Shi X, Weidert ER, Lu P, Xu M, et al. 2013. Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase 3 Sirt3. Mol Cell Biol 33:2047–2055, doi: 10.1128/MCB.01658-12.
21. Kelling CK, Christian BJ, Inhorn SL, Peterson RE. 1985. Hypophagia-induced weight loss in mice, rats, and guinea pigs treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fundam Appl Toxicol 5:700–712, doi: 10.1016/0272-0590(85)90194-0.
22. Koza RA, Nikonova L, Hogan J, Rim JS, Mendoza T, Faulk C, et al. 2006. Changes in gene expression foreshadow diet-induced obesity in genetically identical mice. PLoS Genet 2:e81, doi: 10.1371/journal.pgen.0020081.
23. La Merrill M, Emond C, Kim MJ, Antignac JP, Le Bizec B, Clément K, et al. 2013. Toxicological function of adipose tissue: focus on persistent organic pollutants. Environ Health Perspect 121:162–169, doi: 10.1289/ehp.1205485.
24. Larter CZ, Yeh MM. 2008. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23:1635–1648, doi: 10.1111/j.1440-1746.2008.05543.x.
25. Lee JH, Wada T, Febbraio M, He J, Matsubara T, Lee MJ, et al. 2010. A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology 139:653–663, doi: 10.1053/j.gastro.2010.03.033.
26. Leung HW, Wendl i ng JM, Orth R, Hi l eman F, Paustenbach DJ. 1990. Rel ati ve di stri bution of 2,3,7,8 tetrachlorodi benzo-p-dioxin in human hepatic and adipose tissues. Toxicol Lett 50:275–282.
27. Loomba R, Sanyal AJ. 2013. The global NAFLD epi demi c. Nat Rev Gastroenterol Hepatol 10:686–690, doi: 10.1038/nrgastro.2013.171.
28. Louvet A, Teixeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A, et al. 2011. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 54:1217–1226, doi: 10.1002/hep.24524.
29. Mallat A, Lotersztajn S. 2009. Cigarette smoke exposure: a novel cofactor of NAFLD progression? J Hepatol 51:430–432, doi: 10.1016/j.jhep.2009.05.021.
30. Marra F, Lotersztajn S. 2013. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 19:5250–5269, doi: 10.2174/13816128113199990344.
31. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. 2005. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42:218–224, doi: 10.1016/j. jhep.2004.10.005.
32. Moyer BJ, Rojas IY, Kerley-Hamilton JS, Hazlett HF, Nemani KV, Trask HW, et al. 2016. Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1. Toxicol Appl Pharmacol 300:13–24, doi: 10.1016/j.taap.2016.03.011.
33. NRC (National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals). 2011. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC:National Academies Press.
34. Patsouris D, Reddy JK, Müller M, Kersten S. 2006. Peroxisome proliferator-activated receptor α mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147:1508–1516, doi: 10.1210/en.2005-1132.
35. Pierre S, Chevallier A, Teixeira-Clerc F, Ambolet-Camoit A, Bui LC, Bats AS, et al. 2014. Aryl hydrocarbon receptor-dependent induction of liver fibrosis by dioxin. Toxicol Sci 137:114–124, doi: 10.1093/toxsci/kft236.
36. Postic C, Girard J. 2008. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118:829–838, doi: 10.1172/JCI34275.
37. Sato S, Shirakawa H, Tomita S, Ohsaki Y, Haketa K, Tooi O, et al. 2008. Low-dose dioxins alter gene expression related to cholesterol biosynthesis, lipogenesis, and glucose metabolism through the aryl hydrocarbon receptor-mediated pathway in mouse liver. Toxicol Appl Pharmacol 229:10–19, doi: 10.1016/j.taap.2007.12.029.
38. Shaban Z, El-Shazly S, Abdelhady S, Fattouh I, Muzandu K, Ishizuka M, et al. 2004. Down regulation of hepatic PPARα function by AhR ligand. J Vet Med Sci 66:1377–1386, doi: 10.1292/jvms.66.1377.
39. Shan Q, Huang F, Wang J, Du Y. 2015. Effects of co-exposure to 2,3,7,8-tetrachlorodibenzo-pdioxin and polychlorinated biphenyls on nonalcoholic fatty liver disease in mice. Environ Toxicol 30:1364–1374, doi: 10.1002/tox.22006.
40. Shi Y, Cheng D. 2009. Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am J Physiol Endocrinol Metab 297:E10–E18, doi: 10.1152/ajpendo.90949.2008.
41. Trauner M, Arrese M, Wagner M. 2010. Fatty liver and lipotoxicity. Biochim Biophys Acta 1801:299–310, doi: 10.1016/j.bbalip.2009.10.007.
42. Van den Berg M, De Jongh J, Poiger H, Olson JR. 1994. The toxicokinetics and metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) and their relevance for toxicity. Crit Rev Toxicol 24:1–74, doi: 10.3109/10408449409017919.
43. Vernon G, Baranova A, Younossi ZM. 2011. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285, doi: 10.1111/j.1365-2036.2011.04724.x.
44. Vezina CM, Walker NJ, Olson JR. 2004. Subchronic exposure to TCDD, PeCDF, PCB126, and PCB153: effect on hepatic gene expression. Environ Health Perspect 112:1636–1644, doi: 10.1289/txg.7253.
45. Wahlang B, Falkner KC, Gregory B, Ansert D, Young D, Conklin DJ, et al. 2013. Polychlorinated biphenyl 153 is a diet-dependent obesogen that worsens non-alcoholic fatty liver disease in male C57BL6/J mice. J Nutr Biochem 24:1587–1595, doi: 10.1016/j. jnutbio.2013.01.009.
46. Wahlang B, Song M, Beier JI, Cameron Falkner K, Al-Eryani L, Clair HB, et al. 2014. Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease. Toxicol Appl Pharmacol 279:380–390, doi: 10.1016/j.taap.2014.06.019.
47. Wang C, Xu CX, Krager SL, Bottum KM, Liao DF, Tischkau SA. 2011. Aryl hydrocarbon receptor deficiency enhances insulin sensitivity and reduces PPAR-α pathway activity in mice. Environ Health Perspect 119:1739–1744, doi: 10.1289/ehp.1103593.
48. Wilson CL, Safe S. 1998. Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses. Toxicol Pathol 26:657–671.
49. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. 2007. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45:1366–1374, doi: 10.1002/hep.21655.
50. Yi SW, Hong JS, Ohrr H, Yi JJ. 2014. Agent Orange exposure and disease prevalence in Korean Vietnam veterans: the Korean Veterans Health Study. Environ Res 133:56–65, doi: 10.1016/j.envres.2014.04.027.
51. Yu ML, Guo YL, Hsu CC, Rogan WJ. 1997. Increased mortality from chronic liver disease and cirrhosis 13 years after the Taiwan “yucheng” (“oil disease”) incident. Am J Ind Med 31:172–175.
52. Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ, Nonalcoholic Steatohepatitis Clinical Research Network. 2011. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 54:753–759, doi: 10.1016/j.jhep.2010.07.040.